- Home
- PRAX vs RDN Comparison
PRAX vs RDN Comparison
Compare PRAX & RDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- RDN
- Stock Information
- Founded
- PRAX 2015
- RDN 1977
- Country
- PRAX United States
- RDN United States
- Employees
- PRAX N/A
- RDN N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- RDN Property-Casualty Insurers
- Sector
- PRAX Health Care
- RDN Finance
- Exchange
- PRAX Nasdaq
- RDN Nasdaq
- Market Cap
- PRAX 4.0B
- RDN 4.5B
- IPO Year
- PRAX 2020
- RDN 1992
- Fundamental
- Price
- PRAX $179.18
- RDN $35.48
- Analyst Decision
- PRAX Strong Buy
- RDN Hold
- Analyst Count
- PRAX 12
- RDN 4
- Target Price
- PRAX $212.42
- RDN $38.00
- AVG Volume (30 Days)
- PRAX 978.5K
- RDN 805.5K
- Earning Date
- PRAX 11-05-2025
- RDN 11-04-2025
- Dividend Yield
- PRAX N/A
- RDN 2.88%
- EPS Growth
- PRAX N/A
- RDN 3.60
- EPS
- PRAX N/A
- RDN 4.00
- Revenue
- PRAX $7,463,000.00
- RDN $1,273,225,000.00
- Revenue This Year
- PRAX N/A
- RDN N/A
- Revenue Next Year
- PRAX $44.43
- RDN $2.60
- P/E Ratio
- PRAX N/A
- RDN $9.00
- Revenue Growth
- PRAX 364.98
- RDN 2.49
- 52 Week Low
- PRAX $26.70
- RDN $29.32
- 52 Week High
- PRAX $206.71
- RDN $38.84
- Technical
- Relative Strength Index (RSI)
- PRAX 62.04
- RDN 60.89
- Support Level
- PRAX $159.74
- RDN $33.68
- Resistance Level
- PRAX $188.53
- RDN $35.94
- Average True Range (ATR)
- PRAX 13.41
- RDN 0.85
- MACD
- PRAX -5.00
- RDN 0.24
- Stochastic Oscillator
- PRAX 47.30
- RDN 83.12
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one business segment Mortgage Insurance. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for the benefit of mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans, and also offers other credit risk management solutions, including contract underwriting, to customers. It also provides other mortgage and real estate products and services through Mortgage Conduit, Title, Real Estate Services, and Real Estate Technology businesses.